Panbela Therapeutics, Inc.
PBLADelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001029125
Panbela Therapeutics, Inc. was delisted in 2026; its insiders filed their last Form 4 on Nov 19, 2024; no institution reported holding it in 13F filings for Q4 2025; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 0
- Q4 2025
- 13F value
- $0
- Reported value at the end of Q4 2025
- Superinvestors holding
- 0
- At the end of Q4 2025
Superinvestors holding PBLA, Q4 2025
No superinvestor reported holding PBLA at the end of Q4 2025.
Latest insider trades
Open-market purchases and sales by Panbela Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 19, 2024 (view filing)6:40 PM ET | Nov 15 | 4 days | Soon-Shiong Patrick and 1 other10% Owner | PPurchase | +24.7M | – | – | – | DerivativePrice outlier |
| Nov 13, 2023 (view filing)7:29 PM ET | Nov 8 | 5 days | Goldman Sachs & Co. LLC and 1 other10% Owner | SSale | −72.9K | $0.71 | −$51.7K | −15.5%398.0K after | |
| Feb 1, 2023 (view filing) | Jan 30 | 2 days | Simpson Jennifer K.President and CEO | PPurchase | +4.44K | – | – | +129.8%7.87K after | |
| Feb 1, 2023 (view filing) | Jan 30 | 2 days | Simpson Jennifer K.President and CEO | PPurchase | +8.89K | $0.00 | $0 | –8.89K after | Derivative |
| Feb 1, 2023 (view filing) | Jan 30 | 2 days | Horvath SusanV.P. of Finance & CFO | PPurchase | +4.44K | – | – | +33.1%17.9K after | |
| Feb 1, 2023 (view filing) | Jan 30 | 2 days | Horvath SusanV.P. of Finance & CFO | PPurchase | +8.89K | $0.00 | $0 | –8.89K after | Derivative |
| Oct 6, 2022 (view filing) | Oct 4 | 2 days | Cullen Michael T.Director, 10% Owner | PPurchase | +165.0K | – | – | +80.7%369.6K after | |
| Oct 6, 2022 (view filing) | Oct 4 | 2 days | Cullen Michael T.Director, 10% Owner | PPurchase | +247.0K | $0.00 | $0 | –247.0K after | Derivative |
| Oct 6, 2022 (view filing) | Oct 4 | 2 days | Schemel Donald RobertDirector, 10% Owner | PPurchase | +200.0K | – | – | +70.8%482.7K after | |
| Oct 6, 2022 (view filing) | Oct 4 | 2 days | Schemel Donald RobertDirector, 10% Owner | PPurchase | +300.0K | $0.00 | $0 | –300.0K after | Derivative |
Top 10 13F holders, Q4 2025
The largest institutional positions in Panbela Therapeutics, Inc. at the end of Q4 2025; share changes are against Q3 2025.
No institution reported holding PBLA in 13F filings for Q4 2025.